Loading...

MiMedx Group

DB:MXE
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MXE
DB
$326M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. The last earnings update was 536 days ago. More info.


Add to Portfolio Compare Print
MXE Share Price and Events
7 Day Returns
0%
DB:MXE
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-60.6%
DB:MXE
-10.2%
DE Biotechs
-6%
DE Market
MXE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MiMedx Group (MXE) 0% 0% 6.5% -60.6% -68.2% -44.9%
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • MXE underperformed the Biotechs industry which returned -10.2% over the past year.
  • MXE underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is MiMedx Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether MiMedx Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MiMedx Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MiMedx Group. This is due to cash flow or dividend data being unavailable. The share price is €2.28.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MiMedx Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MiMedx Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MXE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2017-09-30) in USD Not available
OTCPK:MDXG Share Price ** OTCPK (2019-02-04) in USD $2.98
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MiMedx Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for MiMedx Group, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does MiMedx Group's expected growth come at a high price?
Raw Data
DB:MXE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MiMedx Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MiMedx Group's assets?
Raw Data
DB:MXE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2017-09-30) in USD Not available
OTCPK:MDXG Share Price * OTCPK (2019-02-04) in USD $2.98
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x

* Primary Listing of MiMedx Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MiMedx Group's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess MiMedx Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MiMedx Group has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MiMedx Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MiMedx Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MiMedx Group expected to grow at an attractive rate?
  • Unable to compare MiMedx Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MiMedx Group's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare MiMedx Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:MXE Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MXE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MXE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 384 1
2018-12-31 322 1
2017-12-31 323 25 39 2
DB:MXE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2017-09-30 303 59 35
2017-06-30 283 44 21
2017-03-31 264 37 15
2016-12-31 245 26 12
2016-09-30 227 14 20
2016-06-30 212 18 23
2016-03-31 200 14 27
2015-12-31 187 19 29
2015-09-30 175 23 20
2015-06-30 160 24 17
2015-03-31 139 23 11
2014-12-31 118 17 6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MiMedx Group is high growth as no earnings estimate data is available.
  • Unable to determine if MiMedx Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MXE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from MiMedx Group Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MXE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31
2018-12-31
2017-12-31 0.33 0.33 0.33 2.00
DB:MXE Past Financials Data
Date (Data in USD Millions) EPS *
2017-09-30 0.33
2017-06-30 0.20
2017-03-31 0.14
2016-12-31 0.11
2016-09-30 0.19
2016-06-30 0.22
2016-03-31 0.25
2015-12-31 0.28
2015-09-30 0.19
2015-06-30 0.16
2015-03-31 0.11
2014-12-31 0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MiMedx Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. MiMedx Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. MiMedx Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess MiMedx Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MiMedx Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MiMedx Group performed over the past 5 years?

  • MiMedx Group's last earnings update was 536 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MiMedx Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if MiMedx Group's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare MiMedx Group's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare MiMedx Group's 1-year growth to the Europe Biotechs industry average as past earnings data has not been reported.
Earnings and Revenue History
MiMedx Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MiMedx Group Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MXE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-09-30 303.47 35.33 215.81 17.89
2017-06-30 283.32 21.20 204.84 15.32
2017-03-31 264.26 15.10 192.30 13.74
2016-12-31 245.02 11.97 178.91 12.04
2016-09-30 226.97 19.87 168.12 10.92
2016-06-30 211.56 23.10 153.76 10.19
2016-03-31 199.90 26.56 143.64 9.08
2015-12-31 187.30 29.45 133.38 8.41
2015-09-30 175.03 19.90 126.10 7.92
2015-06-30 159.54 17.05 115.40 7.75
2015-03-31 139.43 11.23 103.94 7.49
2014-12-31 118.22 6.22 90.48 7.05
2014-09-30 96.64 0.96 75.49 6.59
2014-06-30 79.24 -3.05 64.00 5.86
2014-03-31 67.18 -3.41 53.68 4.99
2013-12-31 59.18 -4.11 46.20 4.84
2013-09-30 51.70 -4.29 40.10 4.59
2013-06-30 43.53 -8.20 33.14 4.15
2013-03-31 34.90 -8.19 25.32 3.72
2012-12-31 27.05 -7.66 19.59 2.89
2012-09-30 19.18 -8.63 14.93 2.41
2012-06-30 13.38 -6.18 11.53 2.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if MiMedx Group has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if MiMedx Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if MiMedx Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess MiMedx Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MiMedx Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MiMedx Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MiMedx Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as MiMedx Group has not reported sufficient balance sheet data.
  • Unable to establish if MiMedx Group's long term commitments exceed its cash and other short term assets as MiMedx Group has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of MiMedx Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if MiMedx Group has a high level of physical assets or inventory without balance sheet data.
  • Unable to verify if debt is covered by short term assets as MiMedx Group has not reported sufficient balance sheet data.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MiMedx Group Company Filings, last reported 1 year ago.

DB:MXE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2017-09-30 142.47 0.01 36.52
2017-06-30 147.27 0.02 47.53
2017-03-31 129.04 0.02 30.92
2016-12-31 133.00 0.03 34.39
2016-09-30 123.28 0.04 18.34
2016-06-30 121.61 0.07 23.80
2016-03-31 114.24 0.10 17.62
2015-12-31 107.99 0.00 31.49
2015-09-30 100.52 0.16 47.57
2015-06-30 93.24 0.19 45.85
2015-03-31 86.40 0.22 44.70
2014-12-31 89.33 0.00 52.33
2014-09-30 81.26 0.28 47.25
2014-06-30 74.49 0.00 39.25
2014-03-31 76.24 0.00 43.02
2013-12-31 73.57 0.00 44.08
2013-09-30 35.54 0.00 6.06
2013-06-30 32.89 0.00 4.19
2013-03-31 31.59 0.16 5.73
2012-12-31 20.01 4.01 6.75
2012-09-30 19.18 4.67 7.62
2012-06-30 15.67 5.29 2.65
  • Unable to establish if MiMedx Group's level of debt is high without past debt data.
  • Unable to establish if MiMedx Group's debt level has increased without past 5-year debt data.
  • Unable to verify if debt is well covered by operating cash flow as MiMedx Group has not reported sufficient balance sheet data.
  • Unable to confirm if the interest payments on MiMedx Group's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess MiMedx Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MiMedx Group has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MiMedx Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MiMedx Group dividends.
If you bought €2,000 of MiMedx Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MiMedx Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MiMedx Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MXE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MXE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2019-12-31
2018-12-31
2017-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MiMedx Group has not reported any payouts.
  • Unable to verify if MiMedx Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MiMedx Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MiMedx Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MiMedx Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MiMedx Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MiMedx Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MiMedx Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Coles
AGE 53
TENURE AS CEO 0.8 years
CEO Bio

Mr. David J. Coles has been Interim Chief Executive Officer of MiMedx Group, Inc. since July 2, 2018. Mr. Coles has served as CRO of Walter Investment Management, Inc. from June 2017 to February 2018. Mr. Coles was an Interim Chief Executive Officer at Campus Crest Communities, Inc. since April 2015 until January 2016. Mr. Coles serves as Managing Director at Alvarez & Marsal, LLC. He specializes in business performance improvement, profitability analysis and working capital management. He joined Alvarez & Marsal in 1996. He was previously at Arthur Andersen & Co., both in the United Kingdom and in New York. He served as the Chief Executive Officer and Chief Restructuring Officer of National Century Financial Enterprises, Inc from November 2002 to May 2004. He served as the Chief Operating Officer of Applica, Inc from November 2005 to May 2006. He served as a Co-Chief Executive Officer, Chief Operating Officer and Chief Restructuring Officer of Euro-Pro Holdings, Inc. from November 2006 to January 2008. He served as the Chief Restructuring Officer at American Business Financial Services Inc. since March 2005. He served as the Chief Financial Officer, Executive Vice President, Principal Accounting Officer, Treasurer and Controller at Lehman Brothers Holdings, Inc. from September 2008 to February 2009. He served as the Chief Restructuring Officer at Finlay Enterprises Inc. until March 31, 2010. He provides these services for companies within and apart from the bankruptcy process, in senior advisory or interim management roles. His primary areas of concentration are cash flow management while formulating restructuring proposals for underperforming businesses. With over 12 years of financial restructuring experience, he has advised on numerous Chapter 11 proceedings in the capacity of managing the restructuring process, acting as Interim Chief Financial Officer /CRO and running Section 363 auctions. He has also provided expert testimony on valuations and auction process. His assignments include Leiner Health Products Inc. from January 2001 to April 2002 where, as interim Chief Financial Officer and CRO, managed its operational reengineering and financial restructuring and was responsible for restructuring its $285MM senior debt, $85MM bond debt and equity via a prepackaged Chapter XI filing. He also managed the operation and then sale, via a section 363 bankruptcy auction, of 31 hospitals owned by Charter Behavioral Health Systems, LLC and operational improvement at manufacturing subsidiaries of Premark International, Inc, including Florida Tile, West Bend (small electrical appliances) and Precor (fitness equipment). His year long role at Premark was as advisor to the Board of Directors in executing cost reduction and profitability improvements identified through product, process and customer profitability analysis. He served as an Advisor to M*Modal Inc. from 2011 to 2012, he served as an Interim Chief Financial Officer and Interim Executive Vice President of PHH Corporation from March 01, 2011 to April 26, 2012. and his role at this business involved managing internal and external financial reporting, evaluating strategic alternatives, capital raising, rating agency and investor communications, cash flow projection/reporting and working capital improvement. Prior to joining A&M in 1997, he served as a Senior Manager in the turnaround and restructuring group of a Big Five Accounting and Consulting firm in New York, following his transfer from its UK practice in 1992. He managed numerous advisory engagements, conducted investigative reviews of businesses on behalf of lenders and managed companies in receivership. He has served as a Director of Euro-Pro Holdings, Inc. since 2008. He is a Member of the Institute of Chartered Accountants in England and Wales and is a part qualified CFA. Mr. Coles received a B.S. (Hons) in Economics and Accounting from the University of Wales Institute of Science & Technology in Cardiff, UK.

CEO Compensation
  • Insufficient data for David to compare compensation growth.
  • Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the MiMedx Group management team in years:

2
Average Tenure
53
Average Age
  • The tenure for the MiMedx Group management team is about average.
Management Team

Alexandra Haden

TITLE
General Counsel & Secretary
COMPENSATION
$600K
AGE
43
TENURE
4.1 yrs

David Coles

TITLE
Interim Chief Executive Officer
AGE
53
TENURE
0.8 yrs

Ed Borkowski

TITLE
Interim CFO & Executive VP
AGE
60
TENURE
0.8 yrs

Scott Turner

TITLE
Senior Vice President of Operations & Procurement
TENURE
2 yrs

Thomas Koob

TITLE
Chief Scientific Officer
COMPENSATION
$184K
AGE
69
TENURE
12.1 yrs

Thornton Kuntz

TITLE
Senior Vice President of Administration
AGE
64
TENURE
5 yrs

Robert Borchert

TITLE
Vice President of Investor Relations

Mark Graves

TITLE
Chief Compliance Officer
TENURE
0.8 yrs

John Harris

TITLE
Senior Vice President of Marketing & Business Development
AGE
49
TENURE
0.3 yrs

Deborah Dean

TITLE
Executive Vice President of Government & Corporate Affairs
AGE
50
TENURE
6.5 yrs
Board of Directors Tenure

Average tenure and age of the MiMedx Group board of directors in years:

9.6
Average Tenure
73.5
Average Age
  • The tenure for the MiMedx Group board of directors is about average.
Board of Directors

Charlie Evans

TITLE
Chairman & Lead Director
COMPENSATION
$203K
AGE
71
TENURE
0.8 yrs

Larry Papasan

TITLE
Independent Director
COMPENSATION
$223K
AGE
77
TENURE
11.1 yrs

J. Dewberry

TITLE
Independent Director
COMPENSATION
$219K
AGE
74
TENURE
9.6 yrs

Joseph Bleser

TITLE
Independent Director
COMPENSATION
$219K
AGE
73
TENURE
9.6 yrs

Luis Aguilar

TITLE
Independent Non-Employee Director
AGE
64
TENURE
2.1 yrs

Chuck Koob

TITLE
Director
COMPENSATION
$192K
AGE
74
TENURE
11.1 yrs

Glenn Gaston

TITLE
Member of Medical Advisory Board

James Andrews

TITLE
Member of Medical Advisory Board
AGE
75

Bruce Hack

TITLE
Independent Director
COMPENSATION
$198K
AGE
69
TENURE
9.3 yrs

Robert Guldberg

TITLE
Member of Medical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
02. Apr 19 Buy Prescience Investment Group LLC Company 08. Feb 19 15. Mar 19 1,077,975 €2.78 €2,630,119
24. Jan 19 Sell Okumus Fund Management, Ltd. Company 22. Jan 19 23. Jan 19 -1,991,700 €2.53 €-4,907,833
X
Management checks
We assess MiMedx Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MiMedx Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Details
Name: MiMedx Group, Inc.
MXE
Exchange: DB
Founded:
$289,751,054
109,347,613
Website: http://www.mimedx.com
Address: MiMedx Group, Inc.
1775 West Oak Commons Court, NE,
Marietta,
Georgia, 30062,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK MDXG Common Stock Pink Sheets LLC US USD 04. Aug 2008
DB MXE Common Stock Deutsche Boerse AG DE EUR 04. Aug 2008
Number of employees
Current staff
Staff numbers
0
MiMedx Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:33
End of day share price update: 2019/02/04 00:00
Last estimates confirmation: 2019/01/18
Last earnings filing: 2017/10/31
Last earnings reported: 2017/09/30
Last annual earnings reported: 2016/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.